The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
出版年份 2016 全文链接
标题
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
作者
关键词
Empagliflozin, Macroalbuminuria, Microalbuminuria, Sodium glucose cotransporter 2, Type 2 diabetes, Urine albumin-to-creatinine ratio
出版物
DIABETOLOGIA
Volume 59, Issue 9, Pages 1860-1870
出版商
Springer Nature
发表日期
2016-06-18
DOI
10.1007/s00125-016-4008-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
- (2015) Yuliya Lytvyn et al. Canadian Journal of Diabetes
- Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
- (2015) Mark E. Molitch et al. KIDNEY INTERNATIONAL
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
- (2014) I. H. de Boer et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Long-Term Outcomes of Japanese Type 2 Diabetic Patients With Biopsy-Proven Diabetic Nephropathy
- (2013) M. Shimizu et al. DIABETES CARE
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
- (2012) Hiddo J. Lambers Heerspink et al. KIDNEY INTERNATIONAL
- Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
- (2012) Horacio Osorio et al. Oxidative Medicine and Cellular Longevity
- Relation of Albuminuria to Angiographically Determined Coronary Arterial Narrowing in Patients With and Without Type 2 Diabetes Mellitus and Stable or Suspected Coronary Artery Disease
- (2011) Philipp Rein et al. AMERICAN JOURNAL OF CARDIOLOGY
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
- (2010) Dick de Zeeuw et al. LANCET
- Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats
- (2008) Slava Malatiali et al. Experimental Diabetes Research
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
- (2008) L. Vogt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started